Literature DB >> 15977213

Successful carboplatin desensitization in patients with proven carboplatin allergy.

Ronit Confino-Cohen1, Amiram Fishman, Marco Altaras, Arnon Goldberg.   

Abstract

BACKGROUND: Carboplatin is one of the most useful and well tolerated cytotoxic drugs for gynecologic malignancies. Hypersensitivity to carboplatin is not rare among patients receiving multiple recurrent treatments with this drug. The aim of the current study was to offer a safe and convenient carboplatin desensitization strategy to patients with a proven allergic reaction to this drug.
METHODS: Patients with an immediate objective allergic reaction to carboplatin were skin tested with the drug. A 6-hour carboplatin desensitization protocol was administered to the patients with a carboplatin-positive skin test on each of the following treatment courses.
RESULTS: Twenty-three patients with an allergic reaction to carboplatin and a positive skin test were included in the current study. Twenty patients (86.9%) were desensitized. One patient developed a mild urticarial rash. Nineteen patients tolerated 80 desensitization courses uneventfully.
CONCLUSIONS: The data presented a successful desensitization protocol for individuals with a proven allergic reaction to carboplatin. The protocol was safe and convenient and offered an effective therapeutic strategy to patients who required this drug. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977213     DOI: 10.1002/cncr.21168

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

2.  Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report.

Authors:  Tadahiro Shoji; Eriko Takatori; Yoshitaka Kaido; Seisuke Kumagai; Satoshi Takeuchi; Akira Yoshizaki; Toru Sugiyama
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

3.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

Review 4.  Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Authors:  Joana Caiado; Mariana Castells
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

5.  Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors.

Authors:  Xiaolin Ma; Xiuqin Li
Journal:  Int J Clin Oncol       Date:  2018-08-04       Impact factor: 3.402

6.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

7.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

8.  4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

Authors:  Naoto Takase; Koji Matsumoto; Takuma Onoe; Akihito Kitao; Maki Tanioka; Yoshitaka Kikukawa; Satoshi Yamaguchi; Kiyoshi Fujiwara; Shunichi Negoro
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

9.  Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies.

Authors:  Yu-Hsiao Tai; Yi-Jou Tai; Heng-Cheng Hsu; Shu-Ping Lee; Yun-Yuan Chen; Ying-Cheng Chiang; Yu-Li Chen; Chi-An Chen; Wen-Fang Cheng
Journal:  Front Pharmacol       Date:  2017-11-06       Impact factor: 5.810

10.  Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Authors:  D H Moon; J-M Lee; A M Noonan; C M Annunziata; L Minasian; N Houston; J L Hays; E C Kohn
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.